MCID: SKN015
MIFTS: 65

Skin Carcinoma

Categories: Cancer diseases, Rare diseases, Skin diseases

Aliases & Classifications for Skin Carcinoma

MalaCards integrated aliases for Skin Carcinoma:

Name: Skin Carcinoma 12 56 15 17
Skin Cancer 12 54 56 44 15 3
Melanoma and Non-Melanoma Skin Cancer 12
Malignant Neoplasm of Skin 12
Carcinoma of Skin 12
Ca - Skin Cancer 12
Cancer of Skin 12
Cancer, Skin 41

Classifications:



External Ids:

Disease Ontology 12 DOID:3451 DOID:4159
MeSH 45 D012878
NCIt 51 C2920 C4914
SNOMED-CT 69 94047004

Summaries for Skin Carcinoma

MedlinePlus : 44 Skin cancer is the most common form of cancer in the United States. The two most common types are basal cell cancer and squamous cell cancer. They usually form on the head, face, neck, hands, and arms. Another type of skin cancer, melanoma, is more dangerous but less common. Anyone can get skin cancer, but it is more common in people who Spend a lot of time in the sun or have been sunburned Have light-colored skin, hair and eyes Have a family member with skin cancer Are over age 50 You should have your doctor check any suspicious skin markings and any changes in the way your skin looks. Treatment is more likely to work well when cancer is found early. If not treated, some types of skin cancer cells can spread to other tissues and organs. Treatments include surgery, radiation therapy, chemotherapy, photodynamic therapy (PDT), and biologic therapy. PDT uses a drug and a type of laser light to kill cancer cells. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

MalaCards based summary : Skin Carcinoma, also known as skin cancer, is related to squamous cell carcinoma and xeroderma pigmentosum, complementation group d. An important gene associated with Skin Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are G-Beta Gamma Signaling and Human cytomegalovirus infection. The drugs Aminolevulinic acid and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and testes, and related phenotypes are Reduced mammosphere formation and growth/size/body region

Disease Ontology : 12 An integumentary system cancer located in the skin that is the uncontrolled growth of abnormal skin cells.

CDC : 3 Learn what skin cancer is, what the symptoms and risk factors are, and how to lower your risk.

Related Diseases for Skin Carcinoma

Diseases in the Skin Carcinoma family:

Skin Carcinoma in Situ

Diseases related to Skin Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 394)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 32.4 CDH1 CTNNB1 IVL PTCH1 PTGS2 TP53
2 xeroderma pigmentosum, complementation group d 31.7 ERCC2 GSTM1 XPA
3 prostate cancer 31.2 CDH1 CDK4 CHGA CTNNB1 JUN KRT8
4 squamous cell carcinoma, head and neck 31.2 CDH1 CDK4 CTNNB1 GSTM1 MYC PTGS2
5 sweat gland cancer 30.9 KRT20 KRT8 TP53
6 basal cell carcinoma 30.5 CTNNB1 ERCC2 GLI1 GSTM1 IVL KRT20
7 xeroderma pigmentosum, variant type 30.2 ERCC2 PTCH1 TP53 XPA
8 small cell carcinoma 30.2 CHGA KRT20 TP53
9 adenoid squamous cell carcinoma 30.2 CDH1 KRT20 KRT8
10 papilloma 30.1 IVL KRT20 KRT8 TP53
11 mutagen sensitivity 30.1 ERCC2 GSTM1 TP53 XPA
12 adenoid cystic carcinoma 30.0 CDH1 CTNNB1 KRT20 TP53
13 lymphoepithelioma-like carcinoma 29.9 CDH1 KRT20 KRT8
14 merkel cell carcinoma 29.8 CHGA KRT20 KRT8 TP53
15 melanoma, cutaneous malignant 1 29.8 CDK4 CTNNB1 MC1R TP53
16 actinic keratosis 29.7 KRT20 MC1R PTGS2 TMC8 TP53
17 adenocarcinoma 29.6 CDH1 CDK4 CTNNB1 MYC PTGS2 TP53
18 ovarian cancer 29.3 CDH1 CDK4 CTNNB1 JUN MYC TP53
19 lung cancer susceptibility 3 29.2 CDH1 CDK4 CTNNB1 JUN KRT20 PTGS2
20 hepatocellular carcinoma 29.1 CDH1 CDK4 CTNNB1 GSTM1 JUN MYC
21 colorectal cancer 29.0 CDH1 CDK4 CTNNB1 GSTM1 JUN KRT20
22 lung cancer 28.8 CDH1 CDK4 CHGA ERCC2 GSTM1 JUN
23 palmoplantar hyperkeratosis with squamous cell carcinoma of skin and 46,xx sex reversal 12.4
24 skin carcinoma in situ 12.2
25 sarcomatoid squamous cell skin carcinoma 12.1
26 plantar verrucous skin carcinoma 12.0
27 skin cancer, non melanoma, childhood 12.0
28 basaloid squamous cell skin carcinoma 12.0
29 acantholytic squamous cell skin carcinoma 12.0
30 clear cell squamous cell skin carcinoma 12.0
31 pigmentation defects-palmoplantar keratoderma-skin carcinoma syndrome 12.0
32 skin squamous cell carcinoma 11.5
33 xeroderma pigmentosum, complementation group f 11.5
34 xeroderma pigmentosum, complementation group a 11.2
35 oculocutaneous albinism 11.2
36 acral lentiginous melanoma 11.2
37 epidermodysplasia verruciformis 1 11.2
38 skin pilomatrix carcinoma 11.2
39 basal cell nevus syndrome 11.1
40 cockayne syndrome b 11.1
41 lentigo maligna melanoma 11.1
42 metatypical basal cell carcinoma 11.0
43 cutaneous adenocystic carcinoma 11.0
44 malignant syringoma 11.0
45 malignant acrospiroma 11.0
46 eccrine papillary adenocarcinoma 11.0
47 pilomatrix carcinoma 11.0
48 xeroderma pigmentosum, complementation group c 11.0
49 anal margin carcinoma 11.0
50 cutaneous mucoepidermoid carcinoma 11.0

Graphical network of the top 20 diseases related to Skin Carcinoma:



Diseases related to Skin Carcinoma

Symptoms & Phenotypes for Skin Carcinoma

GenomeRNAi Phenotypes related to Skin Carcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CDH1 CDK4 CHGA GSTM1 JUN MYC

MGI Mouse Phenotypes related to Skin Carcinoma:

47 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.49 CDH1 CDK4 CHGA CTNNB1 ERCC2 GLI1
2 cellular MP:0005384 10.43 CDH1 CDK4 CTNNB1 ERCC2 GLI1 JUN
3 behavior/neurological MP:0005386 10.41 CDK4 CTNNB1 ERCC2 GLI1 JUN MC1R
4 endocrine/exocrine gland MP:0005379 10.4 CDH1 CDK4 CHGA CTNNB1 ERCC2 GLI1
5 homeostasis/metabolism MP:0005376 10.4 CDH1 CDK4 CHGA CTNNB1 ERCC2 JUN
6 cardiovascular system MP:0005385 10.36 CDH1 CDK4 CHGA CTNNB1 JUN KRT8
7 immune system MP:0005387 10.36 CDH1 CDK4 CTNNB1 ERCC2 JUN KRT8
8 embryo MP:0005380 10.34 CDH1 CDK4 CTNNB1 GLI1 JUN KRT8
9 mortality/aging MP:0010768 10.34 CDH1 CDK4 CHGA CTNNB1 ERCC2 GLI1
10 hematopoietic system MP:0005397 10.31 CDK4 CTNNB1 ERCC2 JUN KRT8 MC1R
11 integument MP:0010771 10.31 CDH1 CDK4 CTNNB1 ERCC2 JUN MC1R
12 digestive/alimentary MP:0005381 10.26 CDH1 CDK4 CTNNB1 GLI1 KRT8 MYC
13 neoplasm MP:0002006 10.23 CDH1 CDK4 CTNNB1 ERCC2 GLI1 MC1R
14 craniofacial MP:0005382 10.21 CTNNB1 GLI1 MC1R MYC PTCH1 TP53
15 nervous system MP:0003631 10.21 CDK4 CHGA CTNNB1 ERCC2 GLI1 JUN
16 no phenotypic analysis MP:0003012 10.14 CDH1 CHGA CTNNB1 GLI1 JUN MC1R
17 limbs/digits/tail MP:0005371 10.13 CTNNB1 GLI1 MC1R MYC PTCH1 TP53
18 hearing/vestibular/ear MP:0005377 10.12 CTNNB1 KRT8 MC1R MYC PTCH1 TP53
19 liver/biliary system MP:0005370 10.11 CDK4 CTNNB1 JUN KRT8 MYC PTGS2
20 muscle MP:0005369 10.08 CDK4 CHGA CTNNB1 MYC PTCH1 PTGS2
21 normal MP:0002873 10.07 CDH1 CDK4 CTNNB1 GLI1 JUN MYC
22 pigmentation MP:0001186 9.97 CDK4 CTNNB1 ERCC2 MC1R MYC PTCH1
23 reproductive system MP:0005389 9.97 CDH1 CDK4 CHGA CTNNB1 ERCC2 GLI1
24 renal/urinary system MP:0005367 9.86 CDK4 CHGA CTNNB1 GLI1 PTCH1 PTGS2
25 skeleton MP:0005390 9.61 CTNNB1 ERCC2 JUN MYC PTCH1 PTGS2
26 vision/eye MP:0005391 9.28 CDK4 CTNNB1 ERCC2 JUN PTCH1 PTGS2

Drugs & Therapeutics for Skin Carcinoma

Drugs for Skin Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 474)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 106-60-5 137
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
3
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2 4342-03-4 5351166
4
Vindesine Approved, Investigational Phase 4 59917-39-4, 53643-48-4 40839
5
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 22916-47-8 4189
6
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492 6473866
7
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
8
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177 70789204
9
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 185243-69-0
10
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
11
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 124-94-7 31307
12
Adalimumab Approved Phase 4,Phase 3,Phase 2 331731-18-1 16219006
13
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99011-02-6 57469
14
Diclofenac Approved, Vet_approved Phase 4,Phase 2,Not Applicable 15307-86-5 3033
15
Bexarotene Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 153559-49-0 82146
16
Tofacitinib Approved, Investigational Phase 4,Phase 3,Phase 2 477600-75-2
17
Acetylcholine Approved, Investigational Phase 4,Phase 2 51-84-3 187
18
Bacitracin Approved, Vet_approved Phase 4,Phase 2 1405-87-4 439542 10909430
19
tannic acid Approved Phase 4,Phase 3,Not Applicable 1401-55-4
20
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
21 Ixekizumab Approved, Investigational Phase 4,Phase 3 1143503-69-8
22
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 137-58-6 3676
23
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
24
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 85898-30-2, 110942-02-4
25
Vemurafenib Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 918504-65-1 23252090 42611257
26
Ipilimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 477202-00-9
27
Acitretin Approved Phase 4,Not Applicable 55079-83-9, 69427-46-9 6437841
28
Atorvastatin Approved Phase 4 134523-00-5 60823
29
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
30
belimumab Approved Phase 4 356547-88-1 5957 10451420
31
Menthol Approved Phase 4 2216-51-5 16666
32
Azathioprine Approved Phase 4 446-86-6 2265
33
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
34
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 1406-16-2
35
Calcitriol Approved, Nutraceutical Phase 4,Not Applicable 32222-06-3 134070 5280453
36 Methyl 5-aminolevulinate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
40 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
42 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Cyclosporins Phase 4,Phase 3,Phase 2
47 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
48 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
49 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 885)
# Name Status NCT ID Phase Drugs
1 Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
2 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
3 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
4 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
5 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
6 Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study Completed NCT00895206 Phase 4 individual adapted immunosuppression;golden standard therapy
7 Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome Completed NCT00266656 Phase 4 Humatrope
8 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation Completed NCT01644396 Phase 4
9 Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients Completed NCT00492895 Phase 4 Discontinuation of Azathioprin
10 Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma Completed NCT00204555 Phase 4 Imiquimod
11 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients Completed NCT02866695 Phase 4 ingenol mebutate gel 0.015%
12 UVB Light and Sunscreen Completed NCT00818467 Phase 4
13 Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head Completed NCT00204542 Phase 4 Diclofenac;Diclofenac
14 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4 bexarotene;bexarotene
15 Safety and Efficacy of Combining nbUVB to Etanercept in Patients Completed NCT00640393 Phase 4 Etanercept
16 Community Based Trial for AMEVIVE® Completed NCT00168753 Phase 4 Alefacept
17 PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis Completed NCT01766440 Phase 4 Calcitriol 3 mcg/g ointment
18 Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis Recruiting NCT02092467 Phase 4 tofacitinib;tofacitinib
19 A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE) Recruiting NCT02099123 Phase 4 Atorvastatin;Placebo (for Atorvastatin)
20 Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer Recruiting NCT01459666 Phase 4 Dysport (abobotulinumtoxinA);Bacteriostatic 0.9% Sodium Chloride (vehicle)
21 Topical Antibiotic Prophylaxis for Eyelids Recruiting NCT03199911 Phase 4 Topical Anti-Infective Product;Topical Ointment
22 A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis Recruiting NCT03573323 Phase 4 Ixekizumab;Guselkumab;Placebo
23 Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation Recruiting NCT03767660 Phase 4 Rapamycin
24 Pain Outcomes Following Intralesional Corticosteroid Injections Recruiting NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
25 Belimumab Assessment of Safety in SLE Active, not recruiting NCT01705977 Phase 4
26 Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% Active, not recruiting NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
27 Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis Active, not recruiting NCT02125279 Phase 4 Calcitriol
28 Menthol for PDT Pain Not yet recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
29 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
30 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
31 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
32 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
33 Acitretin Plasma Levels Under Hemodialysis Withdrawn NCT00488384 Phase 4 Chemopreventive application (Acitretin)
34 CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial Unknown status NCT00799188 Phase 3 Everolimus
35 T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum Unknown status NCT00002811 Phase 3 liposomal T4N5 lotion
36 Virus Early Transcription Factor (VETF) Multicenter Phototherapy Protocol Unknown status NCT00525395 Phase 3
37 Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients Unknown status NCT01729663 Phase 2, Phase 3 interferon alpha 2b
38 Preoperative Acetaminophen and Carbohydrate Loading Completed NCT03131713 Phase 3 Acetaminophen
39 PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
40 Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer Completed NCT00007631 Phase 3 Tretinoin 0.1% cream or placebo
41 Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma Completed NCT01212549 Phase 3
42 Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer Completed NCT00005884 Phase 3 eflornithine
43 Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer Completed NCT00066872 Phase 3 imiquimod
44 Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals. Completed NCT00272428 Phase 3
45 Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer Completed NCT00021255 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Herceptin;Carboplatin
46 Study of Etanercept in the Treatment of Psoriasis in Adult Subjects Completed NCT00121615 Phase 3 etanercept
47 Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer Completed NCT00000479 Phase 3 Aspirin;Vitamin E
48 Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Completed NCT00326898 Phase 3 Sorafenib;Sunitinib
49 Study to Help Understand the Action of the Drug Etanercept for the Adult Patient With Psoriasis Completed NCT00116181 Phase 3 Etanercept
50 Topical Green Tea Ointment in Treatment of Superficial Skin Cancer Completed NCT02029352 Phase 2, Phase 3 Sinecatechins 10%;Placebo

Search NIH Clinical Center for Skin Carcinoma

Genetic Tests for Skin Carcinoma

Anatomical Context for Skin Carcinoma

MalaCards organs/tissues related to Skin Carcinoma:

42
Skin, Kidney, Testes, T Cells, Lymph Node, Brain, Eye

The Foundational Model of Anatomy Ontology organs/tissues related to Skin Carcinoma:

20
The Skin

Publications for Skin Carcinoma

Articles related to Skin Carcinoma:

(show top 50) (show all 3325)
# Title Authors Year
1
Lack of association of metastasis-associated lung adenocarcinoma transcript 1 variants with melanoma skin cancer risk. ( 30870271 )
2019
2
Appropriate use criteria for basal cell carcinoma Mohs surgery at a single center in the face of high-burden skin cancer: a retrospective cohort study. ( 29727201 )
2019
3
Behavior Issues, Skin Cancer, Adolescent Depression, Prostate Cancer, Deprescribing Antipsychotics. ( 30702247 )
2019
4
Immunobiochemical Reconstruction of Influenza Lung Infection-Melanoma Skin Cancer Interactions. ( 30745900 )
2019
5
Long-term experience with radiotherapy for the treatment of non-melanoma skin cancer. ( 30892970 )
2019
6
Investigation of three oncogenic epitheliotropic viruses shows human papillomavirus in association with non-melanoma skin cancer. ( 30788731 )
2019
7
WHO/ILO work-related burden of disease and injury: Protocol for systematic reviews of occupational exposure to solar ultraviolet radiation and of the effect of occupational exposure to solar ultraviolet radiation on melanoma and non-melanoma skin cancer. ( 30792021 )
2019
8
Mobile Teledermatology for Melanoma Detection. Assessment of Validity in the Framework of a Population-based Skin Cancer Awareness Campaign in Northern Italy. ( 30797846 )
2019
9
Skin cancer in organ transplant recipients: Dynamics in the incidence and clinical predictors for the first and subsequent posttransplant non-melanoma-skin cancer. ( 30811675 )
2019
10
Peri-operative delineation of non-melanoma skin cancer margins in vivo with handheld reflectance confocal microscopy and video-mosaicking. ( 30811707 )
2019
11
Coffee, tea, caffeine, and risk of non-melanoma skin cancer in a Chinese population: The Singapore Chinese Health Study. ( 30731173 )
2019
12
Long-term follow-up in patients treated with electrochemotherapy for non-melanoma skin cancer in the head and neck area. ( 30734631 )
2019
13
Occupational differences in standardized mortality ratios for non-melanotic skin cancer and melanoma in exposed areas among individuals with Fitzpatrick skin types III and IV. ( 30761684 )
2019
14
FRAIL scale as a predictor of complications and mortality in older patients undergoing reconstructive surgery for non-melanoma skin cancer. ( 30655763 )
2019
15
Trends in the treatment and prevention of keratinocyte carcinoma (non-melanoma skin cancer). ( 30660857 )
2019
16
Vitamin D enzymes (CYP27A1, CYP27B1, and CYP24A1) and receptor expression in non-melanoma skin cancer. ( 30668811 )
2019
17
Satellite and In-Transit Metastatic Disease in Melanoma Skin Cancer: A Retrospective Review of Disease Presentation, Treatment, and Outcomes. ( 30681423 )
2019
18
Harnessing the gatekeepers of glucocorticoids for chemoprevention of non-melanoma skin cancer. ( 30302860 )
2019
19
PDGFR-induced autocrine SDF-1 signaling in cancer cells promotes metastasis in advanced skin carcinoma. ( 30874597 )
2019
20
Skin cancer precursor immunotherapy for squamous cell carcinoma prevention. ( 30895944 )
2019
21
The 308-nm excimer laser treatment does not increase the risk of skin cancer in patients with vitiligo: A population-based retrospective cohort study. ( 30849210 )
2019
22
Erectile Dysfunction Medications and Skin Cancer: An analysis in US Veterans. ( 30735744 )
2019
23
NP students' knowledge and attitudes toward skin cancer assessments. ( 30789528 )
2019
24
Evaluating healthcare practitioners' views on store-and-forward teledermoscopy services for the diagnosis of skin cancer. ( 30792879 )
2019
25
Skin cancer prevention: a review of current topical options complementary to sunscreens. ( 30801825 )
2019
26
Long-Term Risk of Skin Cancer Among Childhood Cancer Survivors: A DCOG-LATER Cohort Study. ( 30802904 )
2019
27
The Time Has Come to Enhance Skin Cancer Screening for Adult Childhood Cancer Survivors. ( 30802912 )
2019
28
Infrared and Raman Spectroscopic Studies of Molecular Disorders in Skin Cancer. ( 30804143 )
2019
29
Physician-Centered Outcomes for Skin Cancer Treatment: A Single-Day Modified Delphi Process to Assess the Importance of Themes in Skin Cancer Management. ( 30807387 )
2019
30
Nonmelanoma skin cancer in women. ( 30809571 )
2019
31
Applications of SNAP-tag technology in skin cancer therapy. ( 30809593 )
2019
32
Association of sunbed use with skin cancer risk factors in Europe: an investigation within the Euromelanoma skin cancer prevention campaign. ( 30811689 )
2019
33
Prevalence and determinants of sunbed use in thirty European countries: data from the Euromelanoma skin cancer prevention campaign. ( 30811698 )
2019
34
Cancer league actions against sunbed use for skin cancer prevention. ( 30811700 )
2019
35
Automated detection of nonmelanoma skin cancer using digital images: a systematic review. ( 30819133 )
2019
36
How to organize skin cancer care for organ transplant recipients. ( 30821381 )
2019
37
Does integral affect influence intentions to use artificial intelligence for skin cancer screening? A test of the affect heuristic. ( 30822146 )
2019
38
Integrating the Management of Nodal Metastasis Into the Treatment of Nonmelanoma Skin Cancer. ( 30827456 )
2019
39
Immunotherapy in Nonmelanoma Skin Cancer. ( 30837075 )
2019
40
Hydrochlorothiazide and the risk of skin cancer. A scientific statement of the British and Irish Hypertension Society. ( 30842544 )
2019
41
High-Contrast, Low-Cost, 3D Visualization of Skin Cancer Using Ultra-High-Resolution Millimeter-Wave Imaging. ( 30843805 )
2019
42
Prostaglandin D2-ethanolamide induces skin cancer apoptosis by suppressing the activity of cellular antioxidants. ( 30858059 )
2019
43
Skin Cancer Knowledge and Photoprotective Practices of Organ Transplant Recipients. ( 30860618 )
2019
44
"Try to make good hay in the shade, it won't work!" - A qualitative interview study on the perspectives of Bavarian farmers regarding primary prevention of skin cancer. ( 30861096 )
2019
45
Nonmelanoma Skin Cancer Frequency and Risk Factors in Australian Heart and Lung Transplant Recipients. ( 30865218 )
2019
46
Nonmelanoma Skin Cancer in Childhood and Young Adult Cancer Survivors Previously Treated With Radiotherapy. ( 30865918 )
2019
47
Knowledge, Attitudes, and Practices Regarding Skin Cancer and Sun Exposure among Homeless Men at a Shelter in Dallas, TX. ( 30868481 )
2019
48
Formulation, Characterization and In Vitro Cytotoxicity of 5-Fluorouracil Loaded Polymeric Electrospun Nanofibers for The Treatment of Skin Cancer. ( 30868972 )
2019
49
Regular Sunscreen Use and Risk of Mortality: Long-Term Follow-up of a Skin Cancer Prevention Trial. ( 30885518 )
2019
50
Hypopharyngeal Skin Cancer Following Total Laryngectomy and Pectoralis Flap Reconstruction: Case Report and Literature Review. ( 30888639 )
2019

Variations for Skin Carcinoma

Expression for Skin Carcinoma

Search GEO for disease gene expression data for Skin Carcinoma.

Pathways for Skin Carcinoma

Pathways related to Skin Carcinoma according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.02 CTNNB1 GLI1 IVL JUN PTCH1 PTGS2
2
Show member pathways
12.91 CDK4 CTNNB1 JUN MYC PTGS2 TP53
3
Show member pathways
12.81 CDH1 CDK4 CTNNB1 JUN MYC TP53
4
Show member pathways
12.66 CDH1 CTNNB1 JUN PTGS2 TP53
5
Show member pathways
12.65 CDK4 ERCC2 MYC TP53 XPA
6
Show member pathways
12.58 CDH1 CDK4 CTNNB1 GSTM1 JUN MYC
7
Show member pathways
12.4 CTNNB1 GLI1 PTCH1 TP53
8 12.32 CDH1 CDK4 MYC TP53
9 12.27 CDK4 CTNNB1 JUN MYC TP53
10 12.24 CTNNB1 MYC PTCH1 TP53
11 12.05 CDH1 CTNNB1 MYC PTGS2 TP53
12 12.05 CDH1 CDK4 CTNNB1 GLI1 GSTM1 JUN
13 12.04 CTNNB1 GSTM1 JUN TP53
14 11.96 CDK4 MYC PTGS2 TP53
15 11.96 CTNNB1 ERCC2 JUN TP53 XPA
16 11.93 CTNNB1 JUN MYC TP53
17 11.9 CDH1 CDK4 CTNNB1 JUN MYC PTGS2
18 11.89 CDK4 CTNNB1 MYC TP53
19 11.82 CDH1 CDK4 CTNNB1 JUN MYC TP53
20 11.8 CDK4 MYC TP53
21 11.79 CDK4 MYC PTGS2 TP53
22 11.76 CDK4 MYC TP53
23 11.74 GSTM1 MYC PTGS2
24 11.73 CDK4 JUN MYC
25
Show member pathways
11.73 CDH1 CDK4 CTNNB1 JUN MYC PTGS2
26
Show member pathways
11.72 CDK4 JUN PTGS2
27 11.71 CDH1 CTNNB1 JUN MYC
28 11.7 GSTM1 TP53 XPA
29 11.66 CTNNB1 JUN MYC
30 11.66 CDK4 JUN MYC
31 11.66 CDH1 CDK4 MYC TP53
32 11.59 CTNNB1 ERCC2 JUN TP53 XPA
33 11.46 CDK4 MYC TP53
34 11.46 CTNNB1 JUN MYC
35 11.43 CDK4 MYC TP53
36 11.41 JUN MYC PTGS2 TP53
37 11.28 CTNNB1 MYC TP53
38 11.2 ERCC2 GSTM1 XPA
39 11.17 JUN KRT8 PTGS2 TP53
40 10.8 CDH1 CTNNB1

GO Terms for Skin Carcinoma

Cellular components related to Skin Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 CDH1 CDK4 CTNNB1 ERCC2 GLI1 GSTM1
2 perinuclear region of cytoplasm GO:0048471 9.43 CDH1 CDK4 CHGA CTNNB1 PTCH1 TYR
3 flotillin complex GO:0016600 9.16 CDH1 CTNNB1

Biological processes related to Skin Carcinoma according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.89 CDK4 CTNNB1 JUN PTGS2 TP53
2 positive regulation of cell proliferation GO:0008284 9.88 CDK4 CTNNB1 GLI1 JUN MYC PTGS2
3 regulation of cell proliferation GO:0042127 9.86 CDK4 CTNNB1 PTCH1 PTGS2
4 cell proliferation GO:0008283 9.85 CTNNB1 ERCC2 TP53 TYR
5 in utero embryonic development GO:0001701 9.79 CTNNB1 ERCC2 PTCH1
6 positive regulation of fibroblast proliferation GO:0048146 9.74 CDK4 JUN MYC
7 cellular response to UV GO:0034644 9.71 MYC PTGS2 TP53
8 response to UV GO:0009411 9.7 ERCC2 TYR XPA
9 cellular process GO:0009987 9.66 CTNNB1 JUN
10 regulation of osteoblast differentiation GO:0045667 9.65 CTNNB1 GLI1
11 melanin biosynthetic process GO:0042438 9.65 MC1R TYR
12 nucleotide-excision repair GO:0006289 9.65 ERCC2 TP53 XPA
13 UV-damage excision repair GO:0070914 9.64 MC1R XPA
14 negative regulation of blood vessel diameter GO:0097756 9.64 CHGA PTGS2
15 entry of bacterium into host cell GO:0035635 9.63 CDH1 CTNNB1
16 branching involved in ureteric bud morphogenesis GO:0001658 9.63 CTNNB1 MYC PTCH1
17 negative regulation of cell division GO:0051782 9.62 MYC PTCH1
18 positive regulation of DNA-templated transcription, initiation GO:2000144 9.61 CTNNB1 JUN
19 dorsal/ventral pattern formation GO:0009953 9.61 CTNNB1 GLI1 PTCH1
20 positive regulation of smooth muscle cell proliferation GO:0048661 9.6 JUN PTGS2
21 hair cell differentiation GO:0035315 9.58 CTNNB1 ERCC2
22 hair cycle process GO:0022405 9.58 CTNNB1 ERCC2
23 response to organic substance GO:0010033 9.56 CDH1 CDK4 JUN PTGS2
24 positive regulation of transcription, DNA-templated GO:0045893 9.56 CDH1 CTNNB1 ERCC2 GLI1 JUN MYC
25 cellular response to indole-3-methanol GO:0071681 9.51 CDH1 CTNNB1
26 response to estradiol GO:0032355 9.5 CTNNB1 PTCH1 PTGS2
27 liver regeneration GO:0097421 9.37 GLI1 PTCH1
28 ovulation GO:0030728 9.35 PTGS2
29 UV protection GO:0009650 9.33 ERCC2 MC1R XPA
30 cellular response to phorbol 13-acetate 12-myristate GO:1904628 9.29 CDK4
31 response to drug GO:0042493 9.17 CDH1 CDK4 CTNNB1 JUN MYC PTCH1
32 positive regulation of transcription by RNA polymerase II GO:0045944 10.16 CTNNB1 ERCC2 GLI1 JUN MC1R MYC
33 negative regulation of cell proliferation GO:0008285 10.03 CTNNB1 JUN PTCH1 PTGS2 TP53

Molecular functions related to Skin Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.63 CDH1 GSTM1 JUN PTGS2 TYR XPA
2 protein heterodimerization activity GO:0046982 9.62 CTNNB1 JUN TP53 TYR
3 protein binding GO:0005515 9.58 CDH1 CDK4 CTNNB1 ERCC2 GLI1 IVL
4 enzyme binding GO:0019899 9.35 CTNNB1 GSTM1 JUN PTGS2 TP53
5 mechanosensitive ion channel activity GO:0008381 9.26 TMC6 TMC8

Sources for Skin Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....